Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Effect of PD-1/ PD-L1 and statin combination therapy on gastrointestinal toxicity related to immune checkpoint inhibitors and on survival.
Authors
Yinghong Wang
The University of Texas MD Anderson Cancer Center, Houston, TX
Yinghong Wang , Jay Sanjay Shah , Andres Caleb Urias Rivera , Antony Mathew , Anusha Thomas , Mehmet Altan , Dan Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 742)
DOI
10.1200/JCO.2024.42.3_suppl.742
Abstract #
742
Poster Bd #
L17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
First Author: Antoine Italiano
Poster
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
First Author: Sarah Kim
Poster
2020 ASCO Virtual Scientific Program
Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.
First Author: Richard Lee O'Neal
Poster
2020 Genitourinary Cancers Symposium
Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.
First Author: Pier Vitale Nuzzo